We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoparticle Traps Represent a Radical New Method for Treating Viral Infections

By LabMedica International staff writers
Posted on 20 Jan 2014
An Israeli biotechnology start-up company is researching a radically different approach to the problem of preventing and curing viral infections.

Traditional drug treatment attempts to destroy viruses after they already have invaded host cells and caused significant damage by initiating the disease process (fever, nausea, diarrhea, etc.) in the infected individual. More...
A radically new approach to cure viral infections is under development at Vecoy Nanomedicines (Kiryat Ono, Israel).

The Vecoy (a virus decoy) is an artificial nanoparticle coated with viral receptors. The virus reacts to the nanoparticle in the same way it would to a normal target cell, but once trapped inside, it is immobilized and prevented from spreading the infection. Thus, the Vecoy technology successfully addresses the two major challenges of current medication, namely, virus resistance to treatment and toxicity effects.

Results of cell-culture and preclinical studies in Vecoy’s laboratories demonstrate neutralization of 97% percent of viruses in culture with efficacy expected to rise as the technique is refined. The method is patent pending and funding is being secured to conduct animal trials.

“Viruses are one of the most polymorphic and resilient organisms out there,” said Dr. Erez Livneh, CEO of Vecoy Nanomedicines. “They are rapidly changing, and can change anything in their genome, either by changing their exterior so our immune system would not recognize them or by changing their enzymes so that the handful of drugs we have will not affect them anymore. With the current state of overpopulation of our planet and international flights, we are now prone more than ever before to new viral pandemics which will be very hard to contain, and it is just a matter of time. We had better be in a position where we can do something about it.”

Related Links:

Vecoy Nanomedicines



Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Human Estradiol Assay
Human Estradiol CLIA Kit
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.